Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
- Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients. We here provide a consensus review of the diagnosis, staging and systemic treatment of Korean GEP-NET patients. Systemic therapy options and the current Korean expert consensus on these treatments, including somatostatin analogs, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide treatments, and cytotoxic chemotherapies are addressed.
- 김승태; 류백렬; 배우균; 오도연; 오충렬; 유창훈; 이명아; 최혜진
- Issued Date
- Neuroendocrine tumor; Lanreotide; Octreotide; Everolimus; Sunitinib; Peptide receptor radionuclide therapy; Capecitabine; Temozolomide
- CANCER RESEARCH AND TREATMENT
- Citation Volume
- Citation Number
- Citation Start Page
- Citation End Page
Appears in Collections:
- Medicine > Medicine
- Authorize & License
- Files in This Item:
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.